Navigation Links
Oncothyreon to present at BIO Investor Forum 2008
Date:10/24/2008

SEATTLE, Oct. 24 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the 7th Annual BIO Investor Forum in San Francisco on Friday, October 31, 2008 at 8:00 a.m. Pacific Time.

A live and archived webcast of Dr. Kirkman's presentation can be accessed at http://www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
2. Oncothyreon announces prioritization plan for development programs
3. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
4. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
5. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
6. Oncothyreon to receive milestone payment
7. Oncothyreon Reports First Quarter 2008 Financial Results
8. Oncothyreon files investigational new drug application for PX-866 oncology compound
9. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
10. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
11. Oncothyreon announces effectiveness of shelf registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... REGN) today announced that it has joined the Human Vaccines Project, a ... infectious diseases and cancer. , The Human Vaccines Project brings together ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, ... Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February ... than 100 tables for its annual event, which will run from 3:00 p.m. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... has announced a new agreement with Singapore-based Global Stem Cells Network (GSCN) and ... Philippines, Thailand and Singapore in the latest adipose and bone marrow therapies. ...
(Date:2/9/2016)... ... February 08, 2016 , ... Date and time: ... Institute at the Pennsylvania Biotechnology Center of Bucks County, 3805 Old Easton Road, ... College (TCMC) will hold an open house for participants to learn about a ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 Vigilant Solutions announces today ... in Missouri solved two recent ... (LPR) data from Vigilant Solutions. Brian Wenberg ... which the victim was walking out of a convenience store and witnessed an ... to his vehicle, striking his vehicle and leaving the ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
Breaking Biology News(10 mins):